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In discussing the subject of gonadotrophin re-
leasing factor(s) I cannot help but feel that for once 
in my life I am really in tune with the times, since 
the same subject was recently given a lengthy and 
serious airing on a popular morning television pro-
gram and has also been mentioned in the lay press. 
It seems safe to predict that practitioners of gyne-
cological medicine will soon be asked, possibly 
even deluged with demands, to explain the signif-
icance of the releasing factor(s) to their patients. 
I am not sure that what I am going to say here will 
be exactly what these patients should be told, or 
what they will want to hear, but I think it should 
form the basis for a frank representation of the facts. 
What I want to discuss are not the potential 
therapeutic or diagnostic uses of these newly avail-
able compounds, which are really very speculative, 
but certain features of the physiological control 
system in which these compounds are thought to 
play key roles. Any rational system of therapeutics 
or prophylaxis involving these releasing factors, or 
their derivatives, must be based on an adequate 
understanding of ( 1) the physiological roles of these 
compounds, (2) how these roles may be altered by 
disease, and (3) the effects specific disturbances of 
the control system ( s) in which they operate can be 
expected to have on reproductive processes. 
I will not review the background for my 
remarks in detail, since I have recently done that 
elsewhere (Bogdanove, 1972). The relevant litera-
ture is quite extensive but efforts to synthesize 
meaningful interpretations of it have not been 
lacking. There are several recent or imminent re-
view articles,t and even an entire book (Meites, 
* Presented at the 43rd Annual McGuire Lecture 
Series, December 2, 1971, at the Medical College of Vir-
ginia, Richmond. 
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1970), which would be particularly helpful as keys 
to this literature. 
It is generally accepted today that many if not 
all of the secretory functions of the anterior pitui-
tary gland are controlled, at least to some extent, 
by the central nervous system. The vascular link 
between the brain and the pituitary, the hypothal-
amic-pituitary portal system of veins, is viewed as 
the final common pathway of neural control. The 
idea that the neural influences are mediated by 
"neurohumors,"t transmitted to the gland by these 
portal veins, was first suggested by Friedgood 
(Friedgood, 1936) and later placed on a solid ex-
perimental footing by G. W. Harris and his associates 
(Harris, 1948; Harris, 1955; Harris and Campbell, 
1966). 
A large body of experimental evidence 
indicates that the pituitary gland secretes little or 
no LH and FSH if it is deprived of contact with the 
hypothalamus, but that the injection of hypothal-
amic extracts can cause these two hormones to be 
secreted. Similar partial or complete dependence 
upon hypothalamic "neurohumoral" support is char-
acteristic of the secretion of TSH, growth hormone, 
and ACTH. However, the hypothalamic influence 
upon the secretion of prolactin has been asserted to 
be inhibitory, rather than stimulatory, since the 
isolated pituitary secretes a lot of prolactin and 
treatment with hypothalamic extracts can suppress 
this hypersecretion. 
t McCann and Porter, 1969; Burgus and Guillemin, 
1970; Schally and Kastin , 1970; Gay, 1972; Saffran, 1972; 
Schally, Kastin, and Arimura, 1972. 
t Although these compounds do originate in the nervous 
system, there is no evidence that they are secreted by 
neurons. The possibility that they may be secreted by 
glial elements (Knigge and Scott, 1970) cannot be over-
looked. 
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The active component(s) of the crude hypo-
thalamic extracts have been frustratingly elusive, so 
much so that some investigators (Schreiber, 1967) 
have occasionally wavered in their faith that they 
would eventually be isolated. Those who held the 
faith, however, (as well as the rest of us) have been 
rewarded by the recent isolation and identification 
of several of the releasing factors* and the con-
sequent preparation of pure molecules by organic 
synthesis. 
The two releasing factors which now appear to 
be important for reproduction are TRH and GnRH. 
It is the identifications of these two molecules which 
have been hailed (quite rightly) as achievements 
worthy of the attention of the news and propa-
ganda media. It is on these two compounds, about 
which the lay public (ever ready to plumb the mys-
teries of sex) will soon be demanding information, 
that my remarks will focus. 
The term "releasing factor" (RF) was coined 
by McCann (McCann, Taleisnik, and Friedman, 
1960) to signify the effect such a compound could 
exert on the cells of the anterior pituitary gland-
causing them to release a portion of their hormonal 
content. Over the past 10 years, this term-RF-
has largely supplanted the earlier name for this 
group of neurohumoral factors-"hypophysiotro-
phins" or "hypophysiotrophic agents" (Guillemin 
and Rosenberg, 1955)-which had a broader de-
notation. The physiological process involved in hor-
mone secretion can be considered to have two 
principal phases: synthesis (or production) of the 
hormone and release of the hormone into the cir-
culation (Gay and Bogdanove, 1968). In the case 
of several of the hormones produced by the adeno-
hypophysis, both phases of the secretory process 
depend upon the integrity of the hypothalamic-
pituitary unit. If either the hypothalamus or the 
vascular connection between the hypothalamus and 
the anterior pituitary lobe is damaged, both release 
and synthesis of the pituitary hormones are im-
paired (Bogdanove, 1972). Under acute experi-
mental conditions, it is much easier to determine 
whether something has stimulated release of a hor-
mone than whether the processes of hormone syn-
thesis have been influenced. 
Figure 1 diagrams the relationship of the rates 
of synthesis and release to the amount of hormone 
stored in the gland (compartment I), as well as the 
relation between the rate of release from the pitui-
*Nair, et al, 1970; Burgus, Dunn, et al, 1969; Baba, 
et al, 1971. 
tary and the levels of the hormone in the circula-
tion. These levels, or titers, are the result of input 
and output rates. When hormone enters the blood 
faster than it leaves, titers increase; when the 
entry rate is less than the exit rate, titers decline. 
The concept is deceptively simple, however, since 
the size of compartment II, which represents the 
serum or plasma volume plus the summed volumes 
of a series of extravascular compartments in equi-
librium with the blood, is not known. Consequently, 
it is not yet possible to establish the amount of 
hormone which has to be added or removed to pro-
duce a given change in serum hormone concentra-
tion. Conversely, it is not yet possible to quantitate, 
from measurement of changes in serum hormone 
concentrations, the causative inequality between the 
entry rate (rate of release of hormone from the 
pituitary into the blood) and the exit rate (the com-
bined rates of destruction and excretion of circulat-
ing hormone) during the time that serum hormone 
titers were changing. One can merely infer that the 
inequality existed. However, since exit rates from 
the blood do not seem to vary as widely as rates 
of entry into the blood, major changes in serum 
hormone levels must reflect major changes in re-
lease rates. 
Since the volume of compartment I can be 
measured by simply weighing the pituitary (at 
least in an experimental animal), it should be a very 
simple matter to relate quantitative changes in in-
trapituitary hormone stores to transient inequalities 
of synthesis (entry) and release (exit) rates. The 
catch lies in establishing changes in intrapituitary 
hormone stores, which poses a number of practical 
problems. The foremost is that sampling of intra-
pituitary hormone levels requires removal of the 
gland. This procedure, in contrast to blood sampling, 
cannot be repeated. However, in theory at least, 
any change in intrapituitary hormone content during 
a finite period of time would have to represent the 
product of that period of time and the algebraic 
sum of the synthesis (entry) and release (exit) 
rates. 
Thus, release of a pituitary hormone can be 
detected, if not measured, solely by observing an 
increase in the concentration of the hormone in the 
circulation. To establish a concomitant change in 
hormone synthesis would be far more difficult. Since 
our conceptions tend to reflect our fields of vision, 
we tend to speak of "releasing factors" simply be-
cause effects on hormone release are more visible 
than effects on hormone synthesis. 
In using the pituitary as a model for illustrating 
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Fig. I-Simplified, 2-compartment model illustrating LH secretory dynamics but convertible to any endocrine subsystem. Arrows 
labeled A (I or II) represent rates of entry into each of the 2 adjacent compartments. Arrows labeled C (I, Ila or Ilx) represent 
total or fractional rates of exit. In compartment I, the pituitary (in the case of LH), AI is the net rate of LH synthesis and CI is 
the rate of LH release. Compartment U, the LH "space" (which seems to approximate the plasma volume) corresponds to the "inner 
pool" of Tait and Burstein. The rate of LH entry from the hypophysis into the LH space (All) must, at all times, be commensurate 
with CI, the LH release rate. Rates Cll0 , and Cllx, especially the latter, might better be drawn as P: to indicate that they represent 
net flux between the LH space and the gonad (Cll0 ) and all other extrahypophysial spaces (Cllx). If entry of LH into the plasma 
from these extrahypophysial spaces (Tait and Burstein's "outer pool") were substantial, the apparent rate of exit (Cllx in our studies) 
would be slower than the true rate and the decay curve would not be described by the simple formula we have used. 
If, in one of the compartments, a transient disequilibrium between A and C occurs, a change in B (stores or content) must result, 
according to the relationship A - C = .:iB, where .:iB is the change in stores during the unit of time selected to express rate. BI can 
be measured (as concentration X weight-content) and BII can be calculated from the concentration of the hormone in the plasma, 
if the distribution volume is known (concentration X distribution volume = total circulating hormone). None of the rates (AI, CI, 
All, Cllx, or Clla) has ever been measured. However, in a relatively steady state, as in a rat castrated 4 or more weeks previously 
(where Clla = 0), .:iBI ~ .:iBll ~ 0 and therefore AI ~CI = All ~ Cllx. 
In the "stop-entry" experiment (acute removal of compartment I by hypophysectomy) All instantaneously becomes zero but 
CIIx, the rate of exit from the plasma, slows gradually. Although Cllx immediately starts to decrease, seemingly as an exponentia 
function of BII, its instantaneous initial (zero time) value, which must about equal the steady state (pre-hypophysectomy) values of 
AI, CI and All, can easily be calculated, as explained in the text. (Redrawn with permission from Gay and Bogdanove. Endocrinology 
82:359, 1968.) 
the input-output relationships involved in the pro-
cesses of secretion, I have focused on the most 
meaningful accessible index of activity-changes in 
serum hormone concentration ( 6.BII in Fig. 1 ) . If 
we wish to focus on hypothalamic secretory activity, 
the problems become very much greater. Figure 2 
illustrates a current concept of how the hypothal-
amus and pituitary are integrated with other organs 
involved in the control of reproductive activity. The 
evolution of this model has been reviewed elsewhere 
(Bogdanove, 1972). For our present purpose, a dis-
cussion of current knowledge of gonadotrophin re-
leasing factor ( s), this model is presented merely to 
locate the subject of discussion. 
As shown in Fig. 2, arrow 3 represents the 
secretion of releasing factors, which act (either 
alone or in conjunction with other internal environ-
mental influences) to induce secretion of pituitary 
gonadotrophic hormones (arrow 4). It is precisely 
this stimulus-response relationship which has pro-
vided the existing operational definitions of the so-
called releasing factors. Thus, a factor which re-
leased FSH was called FSH-RF (Igarashi and 
McCann, 1964). One which released LH was called 
LH-RF, or LRF (McCann, Taleisnik, and Friedman, 
1960). A factor thought to affect FSH synthesis 
(Corbin and Milmore, 1971 ) or prolactin synthesis 
(Nicoll and Fiorindo, 1969) was given still another 
name. One which decreased the rate of prolactin 
release was dubbed PIF or PRIF, for prolactin re-
lease inhibiting factor. In every case, the definition 
was indefinite-there was never any valid reason 
for believing that LRF and FSH-RF were separate 
entities (despite published conclusions to that effect 
which will not be cited here) . As long as the changes 
in pituitary hormone release rates which were ob-
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Fig. 2-Major components of brain-pituitary-gonadal control system. Boxes represent loci (generally organs) of physiological responses 
to stimuli. Arrows, which constitute responses as well as stimuli, represent signals (which may be either neural or humoral). To con-
serve space, some arrows have been numbered: 1) pineal secretion (melatonin?); 2) afferent and efferent neurons; 3) hypophysiotrophin 
secretion; 4) LH, FSH, etc. in portal venous blood; 5) LH, FSH, etc. in peripheral blood; 6a) gonadal steroid secretion; 6b) eggs or 
sperm. 
served-plus any changes which may also have oc-
curred without being detected-had been induced 
by administration of crude, or even partially purified, 
hypothalamic extracts, it was simply impossible to 
attribute the response ( s) to specific components of 
the extracts. Thus, acid extracts of rat (or sheep, 
or pig, or steer) hypothalamus could release TSH, 
growth hormone, ACTH, LH, FSH, and, under 
some conditions, MSH (melanophore-stimulating 
hormone, or intermedin) . At the same time, they 
could inhibit release of prolactin. The extent to 
which these, and other, effects could be attributed 
to the presence of specific hypophysiotrophic 
molecules in these extracts still remains to be deter-
mined. Until all such demonstrations have been re-
produced, using "RFs" of unequivocal purity, our 
views of how the hypothalamus might exert its 
effects on pituitary secretory activity will have to 
remain indefinite. 
This was the urgent reason for the intense and 
sustained efforts of the several laboratories which 
were engaged in the great releasing-factor hunt of 
the last decade. The task of collecting and extract-
ing hundreds of thousands of hypothalamic frag-
ments from sows and cows and ewes, in order to 
obtain, at the end of nearly 10 years, the smidgins 
of purified materials needed to define the chemical 
structures of the RFs, can truly be described as epic. 
The results of these Augean labors have finally begun 
to be visible. The structure of the thyrotrophin re-
leasing hormone TRF (or TRH, using Schally's 
nomenclaturet) was discovered barely a year be-
fore that of the single decapeptide molecule which 
appears able to release both LH and FSH (Baba, 
et al, 1971). The name of this molecule has not 
yet been settled. Schally has given it the quasi-
acronym "LH-RH/FSH-RH," but the same mole-
cule is being prepared synthetically, by Abbott 
Laboratories, under the name of GnRH (for 
gonadotrophin-releasing hormone). 
Far more important than what this compound 
should be called is the question of what it can do; 
t Schally has proposed (Schally, Arimura, et al, 
1968) that the RFs be called RHs (for releasing hor-
mones) on the basis that they ought to be recognized 
as full-fledged members of the community of hormones. 
Guillemin and others (Burgus and Guillemin, 1970; Bog-
danove, 1972) have objected to Schally's terminology, for 
several reasons. Still other nomenclature has recently been 
proposed (Saffran, 1972). Debate about etymological 
propriety seems pointless since these compounds will be 
known best by the names under which they are distributed 
by the pharmaceutical companies which undertake to mass 
produce them. Therefore, despite my previous objections, I 
will refer to Schally's LH-RH/FSH-RH as GnRH. 
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first for the physiologist and subsequently for either 
the physician and his individual patient, or for the 
public health and agricultural scientists who are 
concerned with the control of human apd animal 
fertility on a larger scale. I think the answers to 
these questions are of vital importance, but I do 
not think I or anyone can give them just yet. 
We do not yet know whether GnRH is the only 
factor secreted by the hypothalamus which can in-
fluence LH and FSH secretion. As a matter of fact, 
we do not even know that GnRH is secreted by the 
hypothalamus, but only that it can be extracted from 
it. [The increased LH and FSH releasing activity 
which can be shown in portal venous blood after 
the hypothalamus has been stimulated (Kamberi, 
et al, 1971) , may or may not be due to increased 
GnRH concentration in that blood.] If GnRH is, 
in fact, the only gonadotrophin-releasing factor, what 
is its physiological role? Is it involved In disease? 
How can we make use of it? · 
Much work lies ahead before these questions 
will be answered. If we pause to think for a moment 
about some of the major steps toward our present 
understanding of the pituitary hormones involved in 
reproduction, we may be able to glimpse some par-
allels in the problems which lie ahead in the study 
of hypothalamic hormones. 
The demise of the Aristotelian notion of pitui-
tary function came about when pioneer surgeons and 
physiologists (Crowe, et al, 1910; Smith, 1927) 
removed the gland from the living animal and 
discovered that the major resultant deficiencies 
were not in the production of nasal mucus, but 
in somatic growth (particularly at epiphyseal 
plates) and the activities of what we have now cori:J.e 
to know as the pituitary target glands: thyroid, 
adrenal cortex, and gonads. (Similar deficiencies re-
sult from damage to the hypothalamus or isolation of 
the pituitary from hypothalamic influence.) The 
next steps were to show that injection of extracts 
of anterior pituitary tissue could remedy these varc 
ious deficiencies and that specific fractions of such 
extracts could selectively restore specific functions. 
It is through this substitutive approach that the exis-
tence of seven distinct adenohypophyseal hormones 
was finally defined: LH, FSH, TSH, ACTH, pro-
lactin, growth hormone, and MSH. It took a long 
time to accomplish this partial goal, primarily because 
it took so long to determine the actual structures 
of the macromolecules secreted by the anterior 
pituitary. (In this respect, the oligopeptidic hypo-
thalamic hormones should present much less of an 
obstacle.) 
As sufficiently pure pituitary hormones became 
available it was found that FSH alone could produce 
follicular growth, but not estrogen secretion, in 
hypophysectomized rats (Greep, 1968). If a little 
LH was administered with the FSH, steroid secre-
tion also resulted. Ovulation and formation of a 
corpus luteum required a rapid surge of a large 
amount of LH, superimposed on this "priming" of 
the follicle by FSH and a trace of UJ. Physical 
maintenance of the corpus luteum appeared to re-
quire nothing from the pituitary (corpora lutea sur-
vived for months in hypophysectomized rats) al-
though secretion of luteal hormones did. In the rat 
and mouse, but not in other animals, prolactin was 
found to be luteotrophic, capable of activating the 
secretory machinery of the corpus luteum. In the 
male, FSH alone has been credited with a role in the 
production and maintenance of spermatogenesis 
(Steinberger, 1971 ), while LH is clearly capable qf 
stimulating androgen production by the Leydig cells. 
(The androgen, in turn, stimulates spermatogenesis.) 
The male does not seem to use prolactin as a gona-
dotrophin, although he can use it as a lactogenic 
hormone under certain conditions. 
We are now entering a comparable phase of 
substitutive investigation of the releasing factors. So 
far, only two or three facts have emerged which 
merit comment. One is that the response of the pi-
tuitary to GnRH can be influenced, at least quanti-
tatively, by steroid feedback (long-loop arrow, prob-
ably to box IV, in Fig. 2), as well as by either 
genetic sex or some consequence thereof. The evi-
dence for this is that when identical doses of natural 
porcine GnRH were injected into male and female 
castrated rats which had been pretreated with ovarian 
steroids or testosterone (four groups in all), the re-
sponse in the spayed rats which had been pretreated 
with ovarian steroids greatly exceeded that in the 
similarly pretreated orchidectomized rats and in the 
testosterone-pretreated , castrates of either sex 
(Rennels, et al, 1971). Evidence that steroids can 
act directly at the pituitary level to qualitatively 
alter pituitary activity, presumably by modifying 
the effects of either GnRH or some other hypo-
physiotrophic agent(s), has been presented re-
cently (Kingsley and Bogdanove, 1971). These two 
facts suggest, but do not establish, that it may not 
be necessary to postulate neural participation in 
every change in LH or FSH secretory rate, or every 
shift in the LH:FSH ratio, which may occur under 
physiological or experimental conditions. Thus, al-
though changes in LH and FSH secretion may re-
sult from changes in GnRH secretion, it is also pos-
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Fig. 3-Patterns of radioimmunoassayabje serum LH (up-
per graph) and FSH (lower graph) in women during 16 
presumptively ovulatory cycles. Shaded areas represent 95% 
confidence limits of means. (Reprinted with permission 
from Ross, et al. Rec. Progr. Harm. Res. 26: 1, Academic 
Press, 1970.) 
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Fig. 4- Components of RF assays : a. "Double" bioas~ay, 
in which end-point is an ovarian response; b. "Single" 
bioassay, in w)1ich end-point is a pituitary response deter-
mined by _ radioimmunoassays (RIA) of serum; c. Direct 
assay, .which does not involve any biological response. 
(This trpe of assay is not yet available.) 
sible that changes in the pituitary output of these 
two hormones can occur without any precedent 
change in hypothalamic secretory activity. For this 
to happeq, it would be necessary for pituitary re-
sponsiveness to GnRH to vary under the influence 
of one or several control agents other than GnRH. It 
remains to be determined whether sex steroid feed-
back, which apparently can influence pituitary re-
sponsiveness to releasing factor ( s) under experi-
mental conditions, can also do so under physiological 
conditions. 
Another fact is noteworthy. Both human 
(Gual, et al, 1972) and rat (Tashjian, et al, 1971) 
pituitary cells can be stimulated to release prolactin 
by TRH! The mechanism of this unexpected find-
ing remains to be established. 
As additional synthetic releasing factors become 
available, and additional clever or lucky experiments 
are carried out, a considerable body of data will 
develop. From it, the physiologist will venture, about 
the secretion of endogenous releasing factors, opin-
ions for which today there is not yet a sufficient 
foundation. The aim of substitutive research must 
be to supply the pituitary gland deprived of hypo-
thalamic control with a sufficiently elaborate re-
placement for its natural releasing factor input (a 
sort of prosthetic hypothalamus) , so that its behavior 
will mimic that seen when neural controls are allowed 
to operate. Even from such substitution studies, how-
ever, conclusions should be drawn with caution. The 
caveat I would stress is that substitution studies re-
veal only what a hormone can do, not necessarily 
what it does. As an example of the distinction, con-
sider ihe impression-based on the demonstrable 
proportionality between the amounts of FSH injected 
and the resultant sizes of ovarian follicles-that the 
' ' 
progressive growth of the follicle during the pre-
ovulatory phase of the cycle reflects a progressive 
increase in the rate of FSH secretion. This im-
pression, derived from substitution studies, has not 
been borne out by direct observation. Figure 3 shows 
the patterns of LH and FSH in the serum during 
the menstrual cycle in the human. Note that, during 
the follicular phase of this cycle, serum FSH levels 
do not increase, but actually seem to decline. This 
finding would not have been anticipated on the basis 
of substitution experiments. 
Ultimately, it is always necessary to follow the 
substitutive approach with an analytical one, aimed 
at characterizing patterns of secretion by direct ob-
servation. However, I think it will be some time 
before' direct analysis of releasing factor secretion 
becomes a possibility. For most of the past 10 years, 
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measurements of releasing factor activity have re-
quired a "double bioassay" (Fig. 4) in which the 
effect of the factor on the pituitary (a biological 
response) could be assessed only by bioassay (in-
volving a second biological response) . The order of 
error in such an assay system was usually, perhaps 
always, sufficiently enormous that conclusions had to 
be based on intuitive selection among several pos-
sibilities. The advent of radioimmunoassay methods 
for measuring pituitary hormones very precisely has 
reduced error by eliminating the second, but not the 
first, biological response. I think at least some of 
what has been reported on the basis of double bio-
assays will not bear careful scrutiny using single 
bioassays. 
Total elimination of a bioassay step, through 
development of radioimmunoassays for releasing 
factors, is of course desirable. However, some in-
teresting calculations by Gay (Gay, 1972) are note-
worthy. These calculations, based on substitution 
studies, suggest that the concentrations of releasing 
factor ( s) in the hypothalamic-pituitary portal cir-
culation would have to be 2 to 3 orders of magnitude 
below the limits of sensitivity of any known radio-
immunoassay. In peripheral blood, they would be 
lower still. When this is considered together with 
the fact that there are no methods available for 
sampling portal venous blood in an unanesthetized 
animal, the chances for characterizing patterns of 
spontaneous releasing factor secretion by direct ob-
servation still seem very remote. 
If I have drawn too dismal a picture, I am 
sorry. Schally's gift of GnRH is a great one, and a 
beautiful scientific achievement. To the physiolo-
gist, it is a find comparable to the Rosetta stone, 
without which the system depicted in Fig. 2 could 
never be understood. To the physician, it may prove 
to be a useful diagnostic tool and perhaps even, 
ultimately, to have some therapeutic value. But its 
primary value is that of the key to an unsolved 
puzzle. While the key may now be at hand, the 
solution ( s) to the puzzle must still be worked out. " 
REFERENCES 
BABA, Y., MATSUO, H. , AND SCHALLY, A . v . Structure of 
the porcine LH- and FSH-releasing hormone. II. Confirma-
tion of the proposed structure by conventional sequential 
analysis. Biochem. Biophys. R es. Commun. 44:459, 1971. 
BOGDANOVE, E. M. Chapter 1: Hypothalamic-hypophysial 
interrelationships: Basic Aspects. Reproductive Biology 
(Balin and Glasser, eds.), Amsterdam: Excerpta Medi ca, 
1972. 
BURGUS, R., DUNN, T. F., D ESIDERIO, D., AND GUILLEMIN, 
R. Structure moleculaire du facteur hypothalamique hypo-
physiotrope TRF d'origine ovine: mise en evidence par 
spectrometrie de masse de Ia sequence PCA-His-Pro-NHz. 
C.R. A cad. Sci. Paris 269 : 1870, 1969. 
BuRous, R . AND GuJLLEMIN, R . Hypothalamic releasing 
factors. Ann. R ev. Biochem. 39 :499, 1970. 
CORBIN, A. AND MILMORE, J . E . Hypothalamic control of 
pituitary foll icle stimulating hormone synthesis. Endo-
crinology 89 :426, 1971. 
CROWE, s. J., CUSHING, H., AND HOMANS, J. Experimental 
hypophysectomy. Bull. Johns Hopk. Hosp. 21: 127, 1910. 
FRIEDGOOD, H. B. The nervous control of the anterior 
hypophysis (first presented at the Harvard University Ter-
centenary Celebration, 1936). Reprinted in!. Reprod. Fer-
til., Suppl. 10:3, 1970. 
GAY, V . L. The Hypothalamus : Physiology and clinical 
use of releasing factors. Fertility and Sterility 23 : 50, 1972. 
GAY, V. L. AND BooDANOVE, E . M . Disappearance of endo-
genous and exogenous luteinizing hormone activity from 
the plasma of previously castrated, acutely hypophysec-
tomized rats: An indirect assessment of synthesis and re-
lease rates. Endocrinology 82 : 359, 1968. 
GREEP, R. 0. The saga and the science of the gonado-
trophins. Persp. Bio. Med. 12: 124, 1968. 
GUAL, C . A. , KASTIN, A . J., AND ScHALLY, A. V. Clinical 
experience with the use of hypothalamic releasing factors. 
Rec. Progr. Harm . Res. 28, 1972 (in press). 
GUILLEMIN, R. AND ROSENBERG, B. Humoral hypothalamic 
control of anterior pituita ry: a study with combined tissue 
cultures. Endocrinology 57 :599, 1955. · 
HARRIS, G. W. Neural control of the pituitary gland. Physiol. 
R ev. 28:139, 1948. 
HARRIS, G. W. (ed. ) . N eural Control of the Pituitary 
Gland. London : Arnold, 1955. 
HARRIS, G. w. AND CAMPBELL, J . J. Chapter 4 : The regu-
lation of the secretion of luteinizing hormone and ovula-
tion. The Pituitary Gland (Harris and Donovan, eds.), 
Vol. 2, p. 99. Berkeley : University of California Press, 
1966. 
IGARASHI, M. AND MCCANN, S. M. A hypothalamic follicle 
stimulating hormone-releasing factor. Endocrinology 74:446, 
1964. 
KAMBERI, I. A. , MICAL, R. S ., AND PORTER, J. c. Pituitary 
portal vessel infusion of hypothalamic extract and release 
of LH, FSH, and prolactin. Endocrinology 88 :1294, 1971. 
12 BOGDANOVE: GONADOTROPHIN RELEASING FACTOR(S) 
KINGSLEY, T. R. AND BOGDANOVE, E. M. Direct androgen-
pituitary feedback. Fed. Proc. 30:253, 1971. 
KNIGGE, K. M. AND ScoTT, D. E . Structure and function of 
the median eminence. Am. /. Anat. 129:223, 1970. 
MCCANN, S. M. AND PORTER, J. C. Hypothalamic pituitary 
stimulating and inhibiting hormones. Physiol. Rev. 49:240, 
1969. 
MCCANN, S. M., TALEISNIK, S., AND FRIEDMAN, H. M. LH 
releasing activity in hypothalamic extracts. Proc. Soc. Exp. 
Biol. Med. 104:432, 1960. 
MEITES, J . (ed.), Hypophysiotropic H ormones of the 
Hypothalamus: Assay and Chemistry. Baltimore: Williams 
and Wilkins, 1970. 
NAIR, R. M. G., BARRETT, J. F., BOWERS, C. Y., AND 
ScHALLY, A . V. Structure of porcine thyrotropin releasing 
hormone. Biochemistry 9 :1103, 1970. 
N EUMANN, F., BERSWORDT-WALLRABE, R. VON, ELGER, W., 
STEINBECK, H., HAHN, J. D., AND KRAMER, M. Aspects of 
androgen-dependent events as studied by antiandrogens. 
Recent Progr. Horm. R es. 26:337, 1970. 
NICOLL, C. S. AND FIORJNDO, R. P. Hypothalamic control 
of prolactin secretion. G en. Comp. Endocr. Suppl. 2:26, 
1969. 
RENNELS, E . G., BOGDANOVE, E. M., ARIMURA, A., SAITO, 
M., AND ScHALLY, A. V. Ultrastructural observations of 
rat pituitary gonadotrophs following injection of purified 
porcine LH-RH. Endocrinology 88: 1318, 1971. 
Ross, G. T ., CARGILLE, C . M., LIPSETT, M. B., RAYFORD, 
P. L., MARSHALL, J. R., SCOTT, C. A., AND RODBARD, D . 
Pituitary and gonadal hormones in women during sponta-
neous and induced ovulatory cycles. Rec. Progr. Horm. 
Res. 26 : 1, 1970. 
SAFFRAN, M. Chemistry of the hypothalamic hypophysio-
tropic hormones. Handbook of Physiology-The Pitui-
tary and its Control Mechanisms (Knobil and Sawyer, 
eds.). Am. Physiol. Soc., Washington, D. C., 1972 (in press). 
SCHALLY, A. V., ARIMURA, A., BOWERS, C. Y., KASTJN, A . 
J ., SAWANO, s., AND REDDING, T. w. Hypothalamic neuro-
hormones regulating anterior p1tmtary function. Recent 
Progr. Hormone Res. 24:497, 1968. 
ScHALLY, A. V. AND KAsnN, A . J. The role of sex steroids, 
hypothalamic LH-releasing hormone, and FSH-releasing 
hormone in the regulation of gonadotrophin secretion from 
the anterior pituitary gland. Advances in Steroid Biochemis-
try, Vol. II, p. 41 (Briggs, M. H., ed.). New York: Aca-
demic Press, 1970. 
ScHALLY, A. V., KASTIN, A. J., AND ARIMURA, A. FSH-
releasing hormone and LH-releasing hormone. Vit. and 
Horm. 30, 1972 (in press). 
ScREIBER, V. Thyrotrophin-releasing factor: purification, 
mechanism, and blockage of action (a Review). Neuro-
endocrinology 2:175, 1967. 
SMITH, P. E. The disabilities caused by hypophysectomy 
and their repair. The tuberal syndrome in the rat. /. Am. 
Med. Ass. 88: 158, 1927. 
STEINBERGER, E. Hormonal control of mammalian sper-
matogenesis. Physiol. Rev. 51: l, 1971. 
TASHJIAN, A. H ., JR., BAROWSKY, N. J ., AND JENSEN, D. K. 
Thyrotropin releasing hormone: direct evidence for stimu-
lation of prolactin production by pituitary cells in culture. 
Biochem . Biophys. R es. Commun. 43 :516, 1971. 
